KS-V Peptide was jointly established by three internationally renowned scientists from University of Science and Technology of China, Tsinghua University, and Nankai University. KS-V Peptide possesses a number of international leading core technologies. Our peptide synthesis platform, peptide-based drug discovery and screening platform, structural biology platform, as well as efficacy and pharmacokinetic platforms with a focus on oncology, immunology, and metabolism, offer comprehensive support for integrated drug discovery and development services.
Our KS-V Peptide Discovery Services Platform (KPDS) is dedicated to the exploration and advancement of innovative peptides tailored for diverse applications, including therapeutics and targeted delivery tools. In collaboration with our academic and industrial partners, KPDS provides a comprehensive peptide discovery service encompassing phage display screening, binding affinity testing, structural biology analysis of peptide-receptor complexes, and peptide lead optimization – all within a singular, seamless platform. KPDS enables phage display screening against almost any biological target of interest with high diverse peptide libraries to discover novel peptide hits with high binding affinity and high specificity rapidly (~1 month) with a high success rate (>95%).

Media

---